Starpharma CEO speaks with Proactive at the ASX SMIDcaps Conference Starpharma CEO Cheryl Maley talked with Proactive at the ASX Small and Mid-Cap Conference about its dendrimer technology, oncology treatments and FY26. Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. #StarpharmaHoldingsLimited #ProactiveInvestors #CherylMaley #DrugDelivery #Biotechnology